|
|
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
|
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
|
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Phase 1, Single-Arm, Exploratory Open-Label Study Investigating Safety, Tolerability, and Pharmacokinetics of Subcutaneously Administered EmtinB in Healthy Adult Volunteers
A Phase 1, Randomized, Double-Blind, Placebo Controlled, Dose-Escalation Study Investigating Safety and Tolerability and Pharmacokinetics of Subcutaneously Administered EmtinB in Healthy Adult Volunteers
100 Clinical Results associated with Neuroscientific Biopharmaceuticals Ltd.
0 Patents (Medical) associated with Neuroscientific Biopharmaceuticals Ltd.
100 Deals associated with Neuroscientific Biopharmaceuticals Ltd.
100 Translational Medicine associated with Neuroscientific Biopharmaceuticals Ltd.